Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Ptc Therapeutics (PTCT) over the last 11 years, with Q1 2025 value amounting to $800000.0.

  • Ptc Therapeutics' Other Operating Expenses rose 70000.0% to $800000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 46583.33%. This contributed to the annual value of $4.5 million for FY2024, which is 9649.57% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Other Operating Expenses of $800000.0 as of Q1 2025, which was up 70000.0% from $10.2 million recorded in Q4 2024.
  • Ptc Therapeutics' 5-year Other Operating Expenses high stood at $128.9 million for Q2 2023, and its period low was -$10.8 million during Q3 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $100000.0 (2024), whereas its average is $9.4 million.
  • Data for Ptc Therapeutics' Other Operating Expenses shows a peak YoY increase of 1180000.0% (in 2022) and a maximum YoY decrease of 15206.61% (in 2022) over the last 5 years.
  • Ptc Therapeutics' Other Operating Expenses (Quarter) stood at $12.1 million in 2021, then crashed by 152.07% to -$6.3 million in 2022, then surged by 142.86% to $2.7 million in 2023, then soared by 276.85% to $10.2 million in 2024, then plummeted by 92.14% to $800000.0 in 2025.
  • Its last three reported values are $800000.0 in Q1 2025, $10.2 million for Q4 2024, and -$700000.0 during Q3 2024.